User Tools

Site Tools


Autologous bone marrow mesenchymal stromal cell for neuropathic pain

In recent years, cell therapy with autologous mesenchymal stromal cells (MSCs) has been considered as a potential therapeutic weapon in this entity. Ten patients suffering chronic SCI received 100 million MSCs into subarachnoid space by lumbar puncture (month 1 of the study) and this procedure was repeated at months 4 and 7 until reaching a total doses of 300 million MSCs. Intensity of NP was measured by standard numerical rating scale (VAS) from 0-10, recording scores previous to the first MSCs administration and monthly, until month 10 of follow-up. Months 1, 4, 7 and 10 of the study were selected as time points in order to a statistical analysis by the nonparametric Wilcoxon rank test. Our results showed significant and progressive improvement in NP intensity after the first administration of MSCs (p: 0.003). This study supports the benefit of intrathecal administration of autologous MSCs for the treatment of NP in patients with SCI 1).

Vaquero J, Zurita M, Rico MA, Aguayo C, Fernández C, Gutiérrez R, Rodríguez-Boto G, Saab A, Hassan R, Ortega C. Intrathecal administration of autologous bone marrow stromal cells improves neuropathic pain in patients with spinal cord injury. Neurosci Lett. 2018 Jan 20. pii: S0304-3940(18)30041-7. doi: 10.1016/j.neulet.2018.01.035. [Epub ahead of print] PubMed PMID: 29366770.
autologous_bone_marrow_mesenchymal_stromal_cell_for_neuropathic_pain.txt · Last modified: 2018/02/02 17:45 by administrador